Cargando…
P19. Immunomodulation of blasts in AML-patients (pts) with clinically approved response modifiers to improve anti leukaemic T-cell reactivity: an ex vivo simulation of the clinical situation
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072431/ http://dx.doi.org/10.1186/2051-1426-2-S2-P10 |
| _version_ | 1782322958954397696 |
|---|---|
| author | Schmetzer, H Stankova, Z Deen, D Hirn, A Vokac, Y Kroell, T Buhmann, R Hausmann, A Schmid, C Tischer, J |
| author_facet | Schmetzer, H Stankova, Z Deen, D Hirn, A Vokac, Y Kroell, T Buhmann, R Hausmann, A Schmid, C Tischer, J |
| author_sort | Schmetzer, H |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4072431 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-40724312014-06-27 P19. Immunomodulation of blasts in AML-patients (pts) with clinically approved response modifiers to improve anti leukaemic T-cell reactivity: an ex vivo simulation of the clinical situation Schmetzer, H Stankova, Z Deen, D Hirn, A Vokac, Y Kroell, T Buhmann, R Hausmann, A Schmid, C Tischer, J J Immunother Cancer Poster Presentation BioMed Central 2014-03-12 /pmc/articles/PMC4072431/ http://dx.doi.org/10.1186/2051-1426-2-S2-P10 Text en Copyright © 2014 Schmetzer et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Schmetzer, H Stankova, Z Deen, D Hirn, A Vokac, Y Kroell, T Buhmann, R Hausmann, A Schmid, C Tischer, J P19. Immunomodulation of blasts in AML-patients (pts) with clinically approved response modifiers to improve anti leukaemic T-cell reactivity: an ex vivo simulation of the clinical situation |
| title | P19. Immunomodulation of blasts in AML-patients (pts) with clinically approved response modifiers to improve anti leukaemic T-cell reactivity: an ex vivo simulation of the clinical situation |
| title_full | P19. Immunomodulation of blasts in AML-patients (pts) with clinically approved response modifiers to improve anti leukaemic T-cell reactivity: an ex vivo simulation of the clinical situation |
| title_fullStr | P19. Immunomodulation of blasts in AML-patients (pts) with clinically approved response modifiers to improve anti leukaemic T-cell reactivity: an ex vivo simulation of the clinical situation |
| title_full_unstemmed | P19. Immunomodulation of blasts in AML-patients (pts) with clinically approved response modifiers to improve anti leukaemic T-cell reactivity: an ex vivo simulation of the clinical situation |
| title_short | P19. Immunomodulation of blasts in AML-patients (pts) with clinically approved response modifiers to improve anti leukaemic T-cell reactivity: an ex vivo simulation of the clinical situation |
| title_sort | p19. immunomodulation of blasts in aml-patients (pts) with clinically approved response modifiers to improve anti leukaemic t-cell reactivity: an ex vivo simulation of the clinical situation |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072431/ http://dx.doi.org/10.1186/2051-1426-2-S2-P10 |
| work_keys_str_mv | AT schmetzerh p19immunomodulationofblastsinamlpatientsptswithclinicallyapprovedresponsemodifierstoimproveantileukaemictcellreactivityanexvivosimulationoftheclinicalsituation AT stankovaz p19immunomodulationofblastsinamlpatientsptswithclinicallyapprovedresponsemodifierstoimproveantileukaemictcellreactivityanexvivosimulationoftheclinicalsituation AT deend p19immunomodulationofblastsinamlpatientsptswithclinicallyapprovedresponsemodifierstoimproveantileukaemictcellreactivityanexvivosimulationoftheclinicalsituation AT hirna p19immunomodulationofblastsinamlpatientsptswithclinicallyapprovedresponsemodifierstoimproveantileukaemictcellreactivityanexvivosimulationoftheclinicalsituation AT vokacy p19immunomodulationofblastsinamlpatientsptswithclinicallyapprovedresponsemodifierstoimproveantileukaemictcellreactivityanexvivosimulationoftheclinicalsituation AT kroellt p19immunomodulationofblastsinamlpatientsptswithclinicallyapprovedresponsemodifierstoimproveantileukaemictcellreactivityanexvivosimulationoftheclinicalsituation AT buhmannr p19immunomodulationofblastsinamlpatientsptswithclinicallyapprovedresponsemodifierstoimproveantileukaemictcellreactivityanexvivosimulationoftheclinicalsituation AT hausmanna p19immunomodulationofblastsinamlpatientsptswithclinicallyapprovedresponsemodifierstoimproveantileukaemictcellreactivityanexvivosimulationoftheclinicalsituation AT schmidc p19immunomodulationofblastsinamlpatientsptswithclinicallyapprovedresponsemodifierstoimproveantileukaemictcellreactivityanexvivosimulationoftheclinicalsituation AT tischerj p19immunomodulationofblastsinamlpatientsptswithclinicallyapprovedresponsemodifierstoimproveantileukaemictcellreactivityanexvivosimulationoftheclinicalsituation |